- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01017731
Study of Ramucirumab (IMC-1121B) Therapy and Corrected QT (QTc) Interval Changes
A Study to Evaluate the Relationship Between Ramucirumab (IMC-1121B) Therapy and Corrected QT (QTc) Interval Changes in Patients With Advanced Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- ImClone Investigational Site
-
-
Louisiana
-
Metairie, Louisiana, United States, 70006
- ImClone Investigational Site
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- ImClone Investigational Site
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19111
- ImClone Investigational Site
-
-
Rhode Island
-
Providence, Rhode Island, United States, 02903
- ImClone Investigational Site
-
-
Texas
-
Houston, Texas, United States, 77024
- ImClone Investigational Site
-
-
Washington
-
Seattle, Washington, United States, 98109
- ImClone Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- The participant has histologically documented advanced or metastatic malignant cancer of solid tumor origin which has not responded to standard therapy or for which no standard therapy is available
- The participant has resolution of adverse events from prior anticancer therapies
- Performance status of 0 to 2
- The participant is ≥ 18 years of age
- The participant is able to provide informed written consent and is amenable to compliance with protocol schedules and testing
- The participant has adequate liver, kidney, blood, and blood clotting functions as defined in trial entrance criteria
- The participant agrees to use adequate contraception during the study period and for 8 weeks after the last dose of study treatment
Exclusion Criteria:
- The participant had anticancer therapy within 14 days (6 weeks for nitrosoureas or mitomycin C) prior to entering the study
- The participant had therapeutic radiotherapy within 14 days prior to entering the study
- The participant has ongoing side effects ≥ Grade 2 due to prior anticancer therapy
- The participant has brain or leptomeningeal metastases
- The participant has a history of uncontrolled or severe cardiac disease
- The participant has a history of severe congestive heart failure (CHF)
- The participant has a known history of arterial thrombotic events
- The participant has a known history of significant peripheral arterial disease (PAD)
- The participant has an implantable pacemaker or automatic implantable cardioverter defibrillator (AICD)
- The participant has a history of risk factors for ventricular tachycardia or Torsades de pointes (TdP) [for example, family history (parents or siblings) of long QT syndrome], history of fainting, unexplained loss of consciousness, or convulsions
- The participant has a systolic blood pressure (SBP) of > 150 millimeters of mercury (mmHg) or < 90 mmHg or a diastolic blood pressure (DBP) of < 45 or > 95 mmHg. (Participants with a history of hypertension who are receiving antihypertensive therapy are permitted on study provided blood pressure is within the parameters detailed above)
- The participant has a heart rate < 50 beats per minute (bpm) or > 100 bpm at rest
- The participant has a clinically relevant abnormality on the ECG, preventing an accurate measurement of the QT interval
- The participant is using a medication that is known to prolong the ECG QT interval
- The participant has a known allergy to any of the treatment components including fluoroquinolone antibiotics
- The participant has received an investigational new drug or device within 14 days prior to enrollment into this study (excluding placement of an intravenous access device)
- The participant has undergone major surgery within 28 days prior to enrollment
- The participant has known human immunodeficiency virus (HIV) infection
- The participant, if female, is pregnant or lactating
- The participant is receiving chronic daily treatment with aspirin [> 325 milligrams per day (mg/day)]
- The participant has a concurrent active malignancy other than adequately treated nonmelanomatous skin cancer, other noninvasive carcinoma, or in situ neoplasm
- The participant has psychological, familial, sociological, or geographical conditions which do not permit adequate study follow-up, compliance with the protocol, or signature of Informed Consent
Study Plan
How is the study designed?
Design Details
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: IMC-1121B
Active-control participants (first 16 participants) will receive one dose of moxifloxacin orally 7 days before the first treatment with ramucirumab. All participants will undergo triplicate electrocardiogram (ECG) tests (consisting of three individual ECGs performed consecutively within a period of 4 minutes) and vital signs at various times over the trial period. For Cycle 1, all participants will also receive 2 infusions of diphenhydramine before ramucirumab therapy (the first infusion is 1 day before therapy and the second infusion is 15 minutes before therapy). For Cycles 2, 3, and 4, all participants will receive diphenhydramine 15 minutes before ramucirumab therapy. For Cycle 5 and beyond, diphenhydramine infusions before ramucirumab therapy are at the investigator's discretion. Ramucirumab [10 milligrams per kilogram (mg/kg)] intravenously over 60 minutes, once every 3 weeks for minimum of 9 weeks without a break in between. |
Administered orally
IMC-1121B (Ramucirumab) 10 mg/kg intravenously (IV) over 60 minutes, once every 3 weeks for minimum of 9 weeks.
Other Names:
Administered IV
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline to Cycle 3 in QT/Corrected QT (QTc) Interval Prolongation in Participants
Time Frame: Baseline, Cycle 3 (1 cycle=21 days)
|
All electrocardiogram (ECG) tests were performed in triplicate prior to ramucirumab treatment.
QT is the interval between the Q and T waves and QTc is the QT corrected for heart rate using Fridericia's formula: QTc = QT/RR^0.33
where RR is the interval between 2 R waves.
Each participant's mean QT/QTc value was calculated for each ECG test during Cycle 3 and compared to his/her mean pretreatment QT/QTc value.
The greatest change from baseline during Cycle 3 was reported.
QTc prolongation is defined as a QTc exceeding 10 milliseconds (msec) with a lower 90% confidence interval (CI) exceeding 5 msec at any postdose time points per the International Conference on Harmonization (ICH) E14 guidelines for non-thorough QT studies (ICH 2005; ICH 2008).
Least squares (LS) mean was calculated using a linear mixed model for repeated measures (MMRM) and adjusted for serum concentration.
|
Baseline, Cycle 3 (1 cycle=21 days)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Drug-Related Adverse Events (AEs)
Time Frame: Baseline up to data cut off (approximately 105.6 weeks)
|
Data presented are the number of participants who experienced treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), Grade 3 or higher TEAEs, or adverse events (AEs) leading to discontinuation of treatment that were considered to be related to ramucirumab.
A summary of SAEs and other non-serious AEs, regardless of causality, is located in the Reported Adverse Events section.
|
Baseline up to data cut off (approximately 105.6 weeks)
|
Maximum Concentration (Cmax) During Cycle 1
Time Frame: Cycle 1 [2.25 hours (h), 3.25 h, 4.25 h, 72 h, 168 h, 336 h postdose]
|
Maximum observed concentration of IMC-1121B (ramucirumab) in serum during Cycle 1 (1 cycle=21 days).
|
Cycle 1 [2.25 hours (h), 3.25 h, 4.25 h, 72 h, 168 h, 336 h postdose]
|
Maximum Concentration (Cmax) During Cycle 1, Day 4
Time Frame: Approximately Week 1 (Cycle 1, Day 4)
|
Cmax was summarized once per cycle because participants only received 1 dose of IMC-1121B (ramucirumab) per cycle.
Refer to secondary outcome measure 3 for Cmax during Cycle 1.
|
Approximately Week 1 (Cycle 1, Day 4)
|
Maximum Concentration (Cmax) During Cycle 1, Day 8
Time Frame: Approximately Week 2 (Cycle 1, Day 8)
|
Cmax was summarized once per cycle because participants only received 1 dose of IMC-1121B (ramucirumab) per cycle.
Refer to secondary outcome measure 3 for Cmax during Cycle 1.
|
Approximately Week 2 (Cycle 1, Day 8)
|
Maximum Concentration (Cmax) During Cycle 1, Day 15
Time Frame: Approximately Week 3 (Cycle 1, Day 15)
|
Cmax was summarized once per cycle because participants only received 1 dose of IMC-1121B (ramucirumab) per cycle.
Refer to secondary outcome measure 3 for Cmax during Cycle 1.
|
Approximately Week 3 (Cycle 1, Day 15)
|
Maximum Concentration (Cmax) During Cycle 2
Time Frame: Cycle 2 (predose and 1.25 hours postdose)
|
Cmax was not calculated due to the sparse pharmacokinetic sampling employed on Cycle 2, Day 1.
|
Cycle 2 (predose and 1.25 hours postdose)
|
Maximum Concentration (Cmax) During Cycle 3
Time Frame: Cycle 3 [predose and 1.25 hours (h), 2.25 h, 3.25 h, 4.25 h, 72 h, 168 h, 336 h, and 504 h postdose]
|
The maximum observed serum concentration of IMC-1121B (ramucirumab) at steady state (Cmax,ss) during Cycle 3 (1 cycle=21 days).
|
Cycle 3 [predose and 1.25 hours (h), 2.25 h, 3.25 h, 4.25 h, 72 h, 168 h, 336 h, and 504 h postdose]
|
Area Under Concentration (AUC) During Cycle 1
Time Frame: Cycle 1 [2.25 hours (h), 3.25 h, 4.25 h, 72 h, 168 h, 336 h postdose]
|
The area under the concentration versus time curve from time 0 to infinity [AUC(0-inf)] is reported during Cycle 1 (1 cycle=21 days).
|
Cycle 1 [2.25 hours (h), 3.25 h, 4.25 h, 72 h, 168 h, 336 h postdose]
|
Area Under Concentration (AUC) During Cycle 1, Day 4
Time Frame: Approximately Week 1 (Cycle 1, Day 4)
|
AUC was summarized once per cycle because participants only received 1 dose of IMC-1121B (ramucirumab) per cycle.
Refer to secondary outcome measure 9 for AUC during Cycle 1 (Day 1 through Day 15).
|
Approximately Week 1 (Cycle 1, Day 4)
|
Area Under Concentration (AUC) During Cycle 1, Day 8
Time Frame: Approximately Week 2 (Cycle 1, Day 8)
|
AUC was summarized once per cycle because participants only received 1 dose of IMC-1121B (ramucirumab) per cycle.
Refer to secondary outcome measure 9 for AUC during Cycle 1 (Day 1 through Day 15).
|
Approximately Week 2 (Cycle 1, Day 8)
|
Area Under Concentration (AUC) During Cycle 1, Day 15
Time Frame: Approximately Week 3 (Cycle 1, Day 15)
|
AUC was summarized once per cycle because participants only received 1 dose of IMC-1121B (ramucirumab) per cycle.
Refer to secondary outcome measure 9 for AUC during Cycle 1 (Day 1 through Day 15).
|
Approximately Week 3 (Cycle 1, Day 15)
|
Area Under Concentration (AUC) During Cycle 2, Day 1
Time Frame: Approximately Week 1 (Cycle 2, Day 1)
|
AUC was not calculated due to the sparse pharmacokinetic sampling employed on Cycle 2, Day 1.
|
Approximately Week 1 (Cycle 2, Day 1)
|
Area Under Concentration (AUC) During Cycle 3
Time Frame: Cycle 3 [predose and 1.25 hours (h), 2.25 h, 3.25 h, 4.25 h, 72 h, 168 h, 336 h, and 504 h postdose]
|
The area under the concentration versus time curve over the dosing interval at steady state [AUC(tau,ss)] is reported during Cycle 3 (1 cycle=21 days).
|
Cycle 3 [predose and 1.25 hours (h), 2.25 h, 3.25 h, 4.25 h, 72 h, 168 h, 336 h, and 504 h postdose]
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Central Nervous System Depressants
- Autonomic Agents
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Sensory System Agents
- Anesthetics
- Antineoplastic Agents
- Antiemetics
- Gastrointestinal Agents
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Dermatologic Agents
- Anti-Bacterial Agents
- Hypnotics and Sedatives
- Anesthetics, Local
- Anti-Allergic Agents
- Sleep Aids, Pharmaceutical
- Histamine H1 Antagonists
- Histamine Antagonists
- Histamine Agents
- Antipruritics
- Moxifloxacin
- Ramucirumab
- Diphenhydramine
- Promethazine
Other Study ID Numbers
- 13915
- CP12-0712 (Other Identifier: ImClone Systems)
- I4T-IE-JVBK (Other Identifier: Eli Lilly and Company)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer
-
University of Michigan Rogel Cancer CenterRecruitingCancer Liver | Cancer Brain | Cancer Head &Neck | Cancer PelvisUnited States
-
Cellworks Group Inc.RecruitingCancer | Relapsed Cancer | Refractory CancerUnited States
-
UNC Lineberger Comprehensive Cancer CenterHyundai Hope On WheelsRecruitingCancer | Pediatric Cancer | Survivorship | Cancer MetastaticUnited States
-
Vanderbilt-Ingram Cancer CenterNational Institutes of Health (NIH)Active, not recruitingAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
-
MiRXES Pte LtdRecruitingBreast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Thoracic Cancer | Liver CancerSingapore
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IV Gastric Cancer | Stage IVA Colorectal Cancer | Stage IVA Pancreatic Cancer | Stage IVB Colorectal Cancer | Stage IVB Pancreatic Cancer | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric... and other conditionsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage I Breast Cancer | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage... and other conditionsUnited States
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedGastric Cancer | Pancreatic Cancer | Esophageal Cancer | Rectal Cancer | Colon Cancer | Hepatobiliary CancerUnited States
-
Johns Hopkins UniversityNational Cancer Institute (NCI); National Institute on Minority Health and...Enrolling by invitationCancer | Advanced Cancer | End Stage Cancer | MalignancyUnited States
-
University of California, San FranciscoBristol-Myers Squibb; PfizerTerminatedStage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Metastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Stage IV Colon Cancer | Stage IV Rectal... and other conditionsUnited States
Clinical Trials on Moxifloxacin
-
AiCuris Anti-infective Cures AGCompleted
-
Hoffmann-La RocheCompletedHealthy VolunteersUnited States
-
GlaxoSmithKlineCompletedInfluenza, HumanUnited States
-
University of California, San FranciscoRecruitingAntibiotic Resistance | Ocular Surface Microbiome | Gut ResistomeUnited States
-
Universidade Federal de PernambucoCompletedCataract | Endophthalmitis | Macula EdemaBrazil
-
Heidelberg UniversityBayerCompleted
-
CardioKine Inc.Biogen; Cardiokine Biopharma, LLCCompleted
-
University of KarachiCenter for Bioequivalence Studies and Clinical Research; SAMI Pharmaceutical...CompletedHealthy Individuals | Bioequivalence StudyPakistan
-
Lawson Health Research InstituteSt. Joseph's Healthcare FoundationCompletedAge-Related Macular DegenerationCanada
-
PfizerCompleted